期刊文献+

β-淀粉样肽寡聚体的制备及鉴定

Preparation and identification of oligomeric amyloid-β peptide
原文传递
导出
摘要 [目的]制备β-淀粉样肽(amyloid-βpeptide,Aβ)的可溶性寡聚体。[方法]选取化学合成的Aβ25-35、Aβ1-42及对照肽Aβ35-25,体外37℃孵育7 d制备Aβ寡聚体。采用dot blotting,免疫印迹鉴定Aβ的聚集状态;并通过TUNEL法检测Aβ的神经毒性。[结果]经dot blotting和免疫印迹检测,显示本研究制备获得的Aβ25-35和Aβ1-42均为寡聚体,且Aβ25-35寡聚体的分子量以2 kDa、3 kDa和17 kDa为主,Aβ1-42分子量主要为4kDa和8kDa,而对照肽Aβ35-25并不能形成寡聚体。TUNEL法则显示Aβ25-35寡聚体可以引起SH-SY5Y细胞凋亡。[结论]在体外成功建立制备Aβ寡聚体的方法,且通过形态学实验证实该Aβ有神经毒性,为后续研究阿尔兹海默症的致病机制奠定实验基础。 [ Objective ] Preparation of soluble oligomeric amyloid -β peptide (Aβ). [ Methods ] Chemically synthetic Aβ25 - 35 ,Aβ1 -42 or Aβ35 -25 (control peptide of Aβ25 -35 ) was respectively prepared through 37℃ incubation for 7 days in vitro. The oligomeric form of Aβ was observed and assessed via dot blotting and Western blot. Furthermore,TUNEL staining was used to verify the neurotoxicity of Aβ25 -35 oligomer. [ Results] The dot blotting and Western blot results showed that Aβ25 - 35 and Aβ1 -42 were both oligomers,while Aβ35 -25 was not. Aβ25 -35 oligomers were appeared as a ladder in the molecu- lar weight about 2 kDa,3 kDa and 17 kDa. And Aβ1 -42 oligomers were mainly at 4kDa and 8kDa. In addition,it was shown that Aβ25 -35 oligomer induced SH -SYSY cells apoptosis by TUNEL staining. [ Conclusion] The research successfully established a method of A[3 oligomers preparation in vitro and the Aβ was proved to be neurotoxicity by morphological experiment, which will lay the experimental foundation of pathogenic mechanism of Alzheimer' s disease.
作者 徐岩 侯筱宇
出处 《生物技术》 CAS CSCD 北大核心 2015年第6期569-573,共5页 Biotechnology
基金 国家自然科学基金项目("基于PSD-95信号复合体的beta淀粉样肽神经毒性及其外源性和内源性神经保护机制的研究" No.30873054) 江苏省高校优势学科建设工程资助项目(PAPD)资助
关键词 阿尔兹海默症 Β-淀粉样肽 寡聚体 制备 鉴定 Alzheimer' s disease, amyloid - βpeptide, oligomer, preparation, identification
  • 相关文献

参考文献23

  • 1Yankner BA. Mechanisms of neuronal degeneration in Alzheimer' s disease[ J ]. Neuron, 1996,16 ( 5 ) :921 - 932.
  • 2Haass C, Schlossmacher MG, Hung AY, et al. Amyloid beta - pep- tide is produced by cultured ceils during normal metabolism [ J ]. Nature, 1992,359 (6393) :322 - 325.
  • 3Shoji M, Golde TE, Ghiso J, et al. Production of the Alzheimer amy- loid beta protein by normal proteolytic processing [ J ]. Science, 1992,258 ( 5079 ) : 126 - 129.
  • 4Ferreira ST, Klein WL. The AI3 oligomer hypothesis for synapse failure and memory loss in Alzheimer~ disease[ J]. Neurobiol Learn Mere,2011,96(4) :529 -543.
  • 5Santos AN, Ewers M, Minthon L, et al. Amyloid - 13 oligomers in ce- rebrospinal fluid are associated with cognitive decline in patientswith Alzheimer' s disease[ J]. J Alzheimers Dis,2012,29( 1 ) :171 - 176.
  • 6Fluharty BR, Biasini E, Stravalaci M, et al. An N - terminal frag- ment of the prion protein binds to amyloid - [3 oligomers and inhib- its theimeurotoxicity in vivo [ J]. J Biol Chem, 2013,288 ( 11 ) : 7857 - 7866.
  • 7Tay WM, Huang D, Rosenberry TL, et al. The Alzheimer' s amyloid - [3 ( 1 - 42 ) peptide forms off - pathway oligomers and fibrils that are distinguished structurally by intermolecular organization [ J ]. J Mol Biol,2013,425(14) :2494 -2508.
  • 8Ryan TM, Roberts BR, McColl G, et al. Stabilization of nontoxic A[3 - oligomers : insights into the mechanism of action of hydroxyquin- dines in Alzheimer's disease [ J ]. J Neurosci ,2015,35 (7) :2871 - 2884.
  • 9Yates EA, Legleiter J. Preparation protocols of a[3 ( 1 - 40 ) promote the formation of polymorphic aggregates and altered interactions with lipid bilayers [ J ]. Biochemistry ,2014,53 (45) :7038 - 7050.
  • 10Rosensweig C, Ono K, Murakami K, et al. Preparation of stable amyloid 13 - protein oligomers of defined assembly order [ J]. Methods Mol Bio1,2012,849 ( 1 ) :23 - 31.

二级参考文献13

  • 1Teich AF,Arancio O.Is the amyloid hypothesis of Alzheimer's disease therapeutically relevan(tJ)?Biochem J,2012;446(2):165-77.
  • 2Mrak RE.Microglia in Alzheimer brain:a neuropathological perspective[J].Int Alzheimer's Dis,2012;2012:165021.
  • 3Ladiwala AR,Litt J,Kane RS,et al.Conformational differences between two amyloidβoligomers of similar size and dissimilar toxicity[J].J Biol Chem,2012;287(29):24765-73.
  • 4Lee J,Culyba EK,Powers ET,et al.Amyloid-βforms fibrils by nucleated conformational conversion of oligomers[J].Nat Chem Biol,2011;7(9):602-9.
  • 5Alvira-Botero X,Carro EM.Clearance of amyloid-βpeptide across the choroid plexus in Alzheimer's disease[J].Curr Aging Sci,2010;3(3):219-29.
  • 6Kokubo H,Kayed R,Glabe CG,et al.Soluble Abeta oligomers ultrastruc-turally localize to cell processes and might be related to synaptic dysfunc-tion in Alzheimer's disease brain[J].Brain Res,2005;1031(2):222-8.
  • 7Bruggink KA,Müller M,Kuiperij HB,et al.Methods for analysis of amy-loid-βaggregates[J].J Alzheimer's Dis,2012;28(4):735-58.
  • 8Dahlgren KN,Manelli AM,Stine WB,et al.Oligomeric and fibrillar spe-cies of amyloid-βpeptides differentially affect neuronal viability[J].J Biol Chemis,2002;277(35):32046-53.
  • 9刘元,华茜,雷洪涛,李澎涛.老年斑β淀粉样蛋白的清除机制[J].现代生物医学进展,2008,8(1):152-154. 被引量:4
  • 10王建秀,王德生,段淑荣,赵敬堃,王景贺.原子力显微镜观察不同Aβ聚集状态的研究[J].中国现代医学杂志,2008,18(1):33-35. 被引量:9

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部